OMS302 (phenylephrine and ketorolac injection) 1%/0.3% to maintain intraoperative pupil size and to prevent postoperative ocular pain in cataract surgery with intraocular lens replacement

Abstract

Cataract surgery with intraocular lens replacement is among the most commonly performed surgical procedures worldwide. Various pharmacologic agents are administered topically before and/or after, and a few are delivered intracamerally during, surgery to achieve mydriasis and to treat postoperative pain and inflammation. OMS302 (Omidria™ [phenylephrine and ketorolac injection] 1%/0.3%), a proprietary drug containing phenylephrine and ketorolac, was developed for use during cataract surgery to maintain intraoperative pupil size by preventing miosis and reduce early postoperative ocular pain. Containing no preservatives or bisulfites, OMS302 is formulated in a single-dose, single-patient use vial. Added to a standard 500 ml container of irrigation solution used during the procedure, OMS302 is infused into the anterior chamber with direct action on the iris and other ocular tissues. As the only US FDA-approved drug that is indicated both to prevent miosis and reduce postoperative pain associated with cataract surgery, OMS302 provides a new treatment option for ophthalmic surgeons.